Dexamethasone outshines prednisone in pediatric ALL, but proves more toxic
December 8th 2008Dexamethasone in the induction phase of chemotherapy led to a one-third reduction in the risk of relapse, compared with standard treatment, in pediatric acute lymphoblastic leukemia, according to results of an international trial, which were presented this week at the American Society of Hematology meeting in San Francisco.
Radiology resident compiles staging database
December 2nd 2008CHICAGO-When Roland Talanow, MD, PhD, began his radiology residency, the topic of cancer staging proved to be particularly confounding. In an effort to educate himself and help others, Dr. Talanow has built a free, Web-based database that offers one-stop shopping on cancer staging, including comprehensive information on lymphoma, non-Hodgkin’s lymphoma, and HIV-related lymphoma. Dr. Talanow showcased his Web site, www.cancerstaging.info, at RSNA 2008 (abstract LLR03001-H).
CyBorD combo supports stem cell collection in newly diagnosed multiple myeloma
December 2nd 2008CHICAGO-The combination of cyclophosphamide, bortezomib, and dexamethasone is associated with high rates of response and manageable toxicity among patients with newly diagnosed multiple myeloma, according to results from a single-arm phase II trial.
Neuroendocrine Tumors: Novel Approaches in the Age of Targeted Therapy
December 2nd 2008One hundred years after Oberndorfer coined the word “carcinoid,” neuroendocrine tumors (NETs) are thought to be rare tumors characterized by the capacity for hormone production and often an indolent course. Recent data from population-based registries have shown a significant rise in the diagnosed incidence of NETs over the past 3 decades.
Clara Bloomfield: Buck conventional wisdom always
December 2nd 2008As a preschooler, Clara D. Bloomfield, MD, had visions of Florence Nightingale in her head. At the age of four, she informed her mother that she wanted to become a nurse. “My mother said, ‘Well dear, that’s very nice. But if you want to become a nurse, you might as well become a doctor’,” Dr. Bloomfield told Oncology News International.
New breast cancer program reduces time to treatment
December 2nd 2008In 1993, Laura Esserman, MD, took a trip to the UK and noted that breast cancer diagnosis was handled far diff erently than in the U.S. Because all the breast cancer imaging is done centrally in the UK, physicians offer same-day clinics.
Racially-based disparities in ca on the rise, not due to smoking
December 1st 2008A new study found that recent progress in closing the gap in overall cancer mortality between African Americans and whites may be due primarily to smoking related cancers, and that cancer mortality differences related to screening and treatment may still be increasing. The study is the first to analyze racial and ethnic differences between the two broad categories of disease.
ProStrakan offers patch to prevent nausea and vomiting
December 1st 2008Sancuso (granisetron transdermal system) is now available by prescription in the U.S. for patients with chemotherapyinduced nausea and vomiting. The patch continuously releases granisetron into the bloodstream for up to five consecutive days.
Online tool encourages families to bone up on genetics
December 1st 2008Ohio State University’s Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute have developed a free, online assessment tool that allows individuals to enter their family medical history, and determine their risk for both cancer and coronary heart disease.
Coverting unresectable to resectable: Data still limited
December 1st 2008There is growing agreement with Dr. Falcone-based on limited data-that response rates appear to be increased with FOLFOX plus cetuximab, as compared with FOLFOX alone, for KRAS wild-type patients only, according to Jordan Berlin, MD, associate professor of medicine and clinical director of GI oncology at Vanderbilt University in Nashville.
Ovarian Cancer in the Elderly: Further Considerations
December 1st 2008Piver gives his perspective on the management of epithelial ovarian cancer in the elderly. This subject has been dealt with previously by numerous authors, with a general consensus that advancing age is an independent negative prognostic factor when multivariate statistics are applied to the multiple parameters affecting outcome
Brachytherapy improves treatment in augmented women
December 1st 2008CHICAGO-Targeted radiation of breast cancer after lumpectomy reduces treatment time from six and a half weeks to five days, while reducing pain and improving cosmetic outcome, according to a study presented at RSNA 2008 (abstract SSC19-02).
Marathon effort to support cancer care
December 1st 2008Oncologist Howard Hochster, MD, professor of medicine at New York University Cancer Institute, ran the 2008 New York City Marathon to benefit Team Continuum which provides immediate nonmedical support and assistance to cancer patients and their families.
Standardized chemoembolization boosts HCC survival
December 1st 2008CHICAGO-Results from the largest and longest trial of its kind suggest that patients with intermediate and advanced hepatocellular carcinomas who undergo systematic treatment with three chemotherapeutic agents and arterial embolization plus imaging follow-up have better survival rates than those who undergo nonstandardized chemoembolization regimes.
ACS expert warns that global burden of cancer will skyrocket without prevention
December 1st 2008WASHINGTON, DC-The developing world faces “a tsunami of cancer” without massive tobacco control efforts and programs to stanch infection-related tumors, according to the American Cancer Society’s vice president for epidemiology and surveillance research.
New presurgical strategies render colon mets resectable
December 1st 2008STOCKHOLM-Advances in surgical resection have removed the label of “death sentence” associated with colorectal metastases to the liver and lung. But that means oncologists must take on the task of refining strategies to increase resectability. At ESMO 2008, Alfredo Falcone, MD, of the University of Pisa and Instituto Toscano Tumori in Italy, discussed his approach for creating the ideal conditions for resectability.
21st Century Challenge of Ovarian Cancer in the Elderly
December 1st 2008Given that in the 21st century many believe 70 years of age is the new 60 and 80 years of age is the new 70, any article on ovarian cancer in the elderly depends on one’s definition of elderly. To put this in a 21st century perspective, in a thoughtful article on aging in The New Yorker (“The Way We Age Now,” April 30, 2007), Atul Gawande points out, “for most of our hundred-thousand-year existence-all but the past couple of hundred years-the average life span of human beings has been 30 years or less (research suggests that subjects of the Roman Empire had an average life expectancy of 28 years).